



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/070,128	02/27/2002	Jacques Briand	P51032	9830

20462 7590 04/28/2006

SMITHKLINE BEECHAM CORPORATION
CORPORATE INTELLECTUAL PROPERTY-US, UW2220
P. O. BOX 1539
KING OF PRUSSIA, PA 19406-0939

EXAMINER

SHIBUYA, MARK LANCE

ART UNIT	PAPER NUMBER
1639	

DATE MAILED: 04/28/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/070,128

Applicant(s)

BRIAND, JACQUES

Examiner

Mark L. Shibuya

Art Unit

1639

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 23 January 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-19 is/are pending in the application.
- 4a) Of the above claim(s) 12-16 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-11 and 17-19 is/are rejected.
- 7) ☒ Claim(s) 5,8 and 19 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

DETAILED ACTION

1. Claims 1-19 are pending. Claims 12-16 are withdrawn from consideration as being drawn to a non-elected invention. Claims 1-11 and 17-19 are examined.

Continued Examination Under 37 CFR 1.114

2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/23/2006 has been entered.

Priority

3. This application is the national stage entry of PCT/US00/26949, and claims benefit of Provisional application 60/156,557, filed 9/29/1999.

Claim Objections

4. Claims 5 and 8 are objected to because of the following informalities: There are no spaces separating the terms "1H,3H,11B,13C,15N,19F,29S" in lines 3 and 4 of the claims. Appropriate correction is required.

5. Claim 19 is objected to because of the following informalities: Claim 19 should probably state "one or a mixture of chemical compounds" instead of "one or mixture of chemical compounds".

Claim Rejections - 35 USC § 112

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 1-11 and 17-19 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This rejection is for lack of written description.

The claims are drawn to methods comprising substrates and products "of a target molecule". The specification, for example at p. 8, lines 29-30, contemplate that "[a]n embodiment of the present invention provides a target molecule involved in a catalytic reaction of a substrate into a final product." The specification at, e.g., p. 13, lines 16-19, states that "[t]argets, products, ligands and substrates of the invention may be polypeptides and/or polynucleotides." The specification, at p. 14, lines 17-21, states that "[i]n preferred embodiments each of the wells in a multiwell format is loaded with one or more compounds, an invariant concentration of substrate and/or ligand and/or

product, and an invariant concentration of target, most preferably an enzyme, either of protein or a ribozyme.” The specification at p. 19, Example 1, Figures 1 and 2, describes “deformylation of For-Met-Ala-Ser-OH by Peptide Deformylase (S.Aureus) when 8-hydroxyquinoline is present in the solution.”

Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed.” (See page 1117.) The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See Vas-Cath at page 1116).

One of skill in the art cannot envision the detailed sequence or chemical structure of the encompassed substrates or products of any target molecule, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. In so far as the specification contemplates substrates or products as enzyme substrates or enzyme products, the specification does not describe a representative number of species to adequately describe the broad genus of “target molecules”. The specification states that target molecules may be polypeptides or polynucleotides, however, the specification does not limit the definition of target molecules; and does not limit the definition of target molecules to enzymes. The specification provides a single example wherein the target molecules is a *S. aureus* peptide deformylase, and a single substrate that is For-Met-Ala-Ser-OH. The specification as filed does not describe a single enzyme product,

Art Unit: 1639

including an enzyme product used in the assay, when the target molecule is peptide deformylase. The specification at p. 8, line 33, shows a reaction scheme in which an enzyme product "P", is depicted as not associated with, but separate from an enzyme "E". The specification does not describe what spectrum results when a product and at least one compound is exposed to a target molecule or even to a target molecule that is an enzyme. The specification does not describe a representative number of substrates or products for any target molecule. The specification does not point to where in the art such information exists. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of using it. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

Furthermore, all of the claims, except for claim 9, are drawn generally to a first spectrum and a second spectrum, without limitation as to the type of spectrum. The specification, for example at p. 2, lines 1-2, state that "[t]he present invention relates to methods using one-dimensional and multi-dimensional NMR spectroscopy for identifying ligands to target biomolecules." The specification does not describe any other type of spectroscopy or methodology or generating spectra. Thus the specification does not describe a representative number of species of methodology to adequately describe the genus of methods of generating spectra.

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF's were found to be unpatentable due to lack of written description for that broad class. The specification

provided only the bovine sequence. Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115).

8. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

9. Claims 1-11 and 17-19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 recites the language "at least one chemical compounds" in lines 1-2, which renders the claims vague and indefinite because it is unclear as to how many chemical compounds are referred to.

Claim 1 recites the limitation "a target, a target molecule, the target molecule, and said target molecule" in lines 3, 8, 11, and 17. There is uncertain antecedent bases for these limitations in the claim because it is unclear if the target molecule is the same as "a target molecule" in lines 1-2.

Claim 1 recites the limitation "the transformation" in lines 15-16. There is insufficient antecedent basis for this limitation in the claim.

Claim 2 recites the limitation "a target" in line 1. There is uncertain antecedent basis for this limitation in the claim because it is unclear if the target molecule is the same as "a target molecule" in lines 1-2 of claim 1, (from which claim 2 depends).

Claim 3 recites the limitation "a chemical compound" in lines 1-2. There is uncertain antecedent basis for this limitation in the claim because it is unclear if the chemical compounds is the same as "at least one chemical compounds" in lines 1-2 of claim 1, (from which claim 3 depends).

Claim 4 recites the limitation "a first spectrum" in line 2. There is uncertain antecedent basis for this limitation in the claim because it is unclear if the first spectrum is the same as "a first spectrum" in line 5 of claim 1, (from which claim 4 depends).

Claims 5 and 8 recite apparent Markush groups with improper language, and should probably state "selected from the group consisting of . . . and . . .", instead of "selected from the group consisting of . . . or . . .".

Claim 6 recites the limitation "a mixture" in line 2. There is uncertain antecedent basis for this limitation in the claim because it is unclear if the mixture is the same as "mixture of chemical compounds" in lines 1-2 of claim 1, (from which claim 2 depends).

Claim 19 recites the limitation "a target molecule" in line 3. There is uncertain antecedent basis for this limitation in the claim because it is unclear if the target molecule is the same as "a target molecule" in lines 1-2.

Claim 19, which recites the language "said compounds of step c)" in step d, is confusing because step c) may have only a single chemical compound

Claim Rejections - 35 USC § 102

Maintained Claim Rejections

10. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

11. Claims 1-4, 6, 7, 9-11, 17, 18, and 19 are rejected under 35 U.S.C. 102(e) as being anticipated by Moore et al., (US 2003/0143757). The rejection is maintained for the reasons of record, which are repeated for the convenience of the reader.

The claims are drawn to methods of identifying compounds that interact with a target molecule comprising the steps of: a) mixing a substrate, product or ligand of a target with at least one chemical compounds b) generating a first spectrum that displays either a chemical shift in the first dimension or a chemical shifts in the other dimension of substrate, product or ligand in step a); c) exposing substrate, product or ligand and mixture of chemical compounds in step a) to a target molecule for one or more incubation times; d) generating a second spectrum that displays either a chemical shifts in the first dimension or a chemical shifts in the other dimension of substrate or product in step a) that has been exposed to the target molecule in step c) in the presence of one or mixture of chemical compounds in step a); e) comparing said first spectrum and second spectrum after one or more said incubation times in step c) to determine at least one difference between said first spectrum and second spectrum, the differences observed along either or both chemical shift dimensions identifying the transformation of said substrate and classifying the presence of one or more compounds that are substrates, products or ligands that interact with said target molecule; and variations thereof.

Moore et al., (US 2003/0143757), at para [0052]-[0059], [0075]-[0082], [0139] teaches obtaining an NMR spectrum of a ligand, exposing the ligand to the target and generating a subsequent NMR spectrum of the ligand. Moore et al. state:

According to one preferred embodiment, the determination of binding is achieved by the NMR method of line broadening, relaxation filtering or a combination of the two and comprises the steps of: i) obtaining a one-dimensional NMR spectrum of said drug core in the absence of said target; ii) mixing the target with the drug core at a molar ratio of between 1:1 and 1:100. iii) subjecting said mixture to nuclear magnetic resonance for a period of time sufficient to obtain a one-dimensional spectrum; and iv) comparing the spectra obtained in steps i) and iii) to determine if said drug core has bound to said target.

Moore et al., (US 2003/0143757), at para [0052]-[0056]. Moore contemplates testing multiple drug cores in the same sample, which reads on mixing a substrate, product or ligand with at least one compound, and wherein the mixture comprises between 2 and 100 chemical compounds (claim 6). Moore contemplates targets that are protein, enzymes, peptides, nucleic acids, etc., which are biomolecules (claim 2). Moore teaches individual compartmentalization of compounds wherein the compounds are provided in multi-well plates, or attached to solid media or beads.

Art Unit: 1639

Response to Arguments [Previous Office Action]

Applicant argues that the reference of Moore does not disclose exposing substrate, ligand or product of a target molecule with chemical compounds and generating a spectrum of that mixture. Furthermore, Moore et al. do not disclose exposing this mixture with a target molecule for one or more incubation times and comparing spectra of the target/compound/ligand mixture over time. Finally, Moore, et al. do not monitor a signal generated by a substrate, ligand or product over time. Instead, Moore et al. observe the signal of a chemical compound in a single mixture. Thus, Moore et al. do not identically show each and every element of the independent claims of this invention.

Applicant's arguments filed 03/25/2005 have been fully considered but they are not persuasive. Moore, throughout the publication, and for example, at p. 7, para [0076], disclose NMR analysis of multiple drug cores, reading on generating a spectrum of a mixture of a ligand and chemical compounds, and then generating a second spectrum after incubation of the mixture with target into to identify drug cores. Moore states: "The cross peaks for each individual drug core are then easily identifiable as they appear at the same frequencies as any two diagonal peaks corresponding to that drug core", (Moore at para [0076]).

Response to Arguments

Applicant has amended the claims to be drawn to "substrate or product" rather than "substrate, product or ligand". Applicant argues that the prior art reference of Moore does not teach exposing substrate or product to a target molecule with chemical compounds and generating a spectrum of the substrate or product. Applicant argues that Moore merely discloses obtaining spectra of drug cores with a target molecule.

Applicant's arguments entered 1/23/2006, have been fully considered but they are not persuasive. Claims must be given their broadest reasonable interpretation consistent with the supporting description. In re Hyatt, 211 F.3d 1367, 1372, 54 USPQ2d 1664, 1667 (Fed. Cir. 2000). The specification as filed does not provide a limiting definition of the terms "substrate" or "product". Applicant does not indicate whether or how the terms "substrate" or "product" distinguish over the prior art.

It is unclear why applicant believes that the prior art does not disclose exposing a substrate or product to a target molecule with chemical compounds and generating a

Art Unit: 1639

spectrum of the substrate or product. Moore teaches generating a spectrum of nicotinic acid and 2-phenoxy benzoic acid after exposure to the target molecule p38 MAP kinase.

12. Claims 1-11, 18, and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Thompson et al., Proc. Natl. Acad. USA, Vol. 94, pp. 14249-14254 (Dec. 1997). The rejection is maintained for the reasons of record, which are repeated for the convenience of the reader.

Thompson et al. at the abstract, p. 14249, para 5-p. 14250, para 3, Fig. 1, p. 14252, para 3, Fig. 4, teach the proton NMR characterization of inhibitors of the cysteine protease, a biomolecule, wherein the inhibitors were synthesized with the isotope ^3H ; followed by NMR analysis of cathepsin K adducts with inhibitors, wherein the protease and inhibitors are incubated with 2-(*N*-morpholino)ethane-sulfonic acid (Mes)/NaCl/Cys for fixed times depending upon inhibitor concentration, whereupon the reactions are quenched by dialysation into 90% water/10% D_2O , 50 mM acetate- d_3 , 250 mM NaCl, and 2mM L-Cys.

Response to Arguments [Previous Office Action]

Applicant argues that the reference of Thompson does not disclose exposing substrate, ligand or product of a target molecule with chemical compounds and generating a spectrum of that mixture. Furthermore, Thompson et al. do not disclose exposing this mixture with a target molecule for one or more incubation times and comparing spectra of the target/compound/ligand mixture over time. Finally, Thompson et al. do not monitor a signal generated by a substrate, ligand or product over time. Instead, Thompson et al. observe the signal of a chemical compound in a single mixture. Thompson merely discloses a selectively double-labeled inhibitor alone or with cathepsin K. Applicant argues that a single sample was prepared for NMR analysis, as shown in Figure 4. Thus Thompson et al. do not identically show each and every element of the independent claims of this invention.

Applicant's arguments filed 03/25/2005 have been fully considered but they are not persuasive. Thompson et al. at p. 12250, para 3, teach that the samples for NMR are dialyzed into 90% water/10% D_2O , acetate- d_3 , NaCl and L-Cys, which read on the at least one chemical compounds mixed with a ligands of the target. The examiner respectfully notes that the claims are broadly drawn to any chemical compound in the mixture.

Response to Arguments

Applicant has amended the claims to be drawn to "substrate or product" rather than "substrate, product or ligand". Applicant argues that Thompson teaches spectra of the inhibitor and not of the substrate or product.

Applicant's arguments entered 1/23/2006, have been fully considered but they are not persuasive. Claims must be given their broadest reasonable interpretation consistent with the supporting description. In re Hyatt, 211 F.3d 1367, 1372, 54 USPQ2d 1664, 1667 (Fed. Cir. 2000). The specification as filed does not provide a limiting definition of the terms "substrate" or "product". Applicant does not indicate whether or how the terms "substrate" or "product" distinguish over the prior art.

13. Claims 1-11, 18, and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Hajduk et al., J. Am. Chem. Soc. 1997, vol. 119, pp. 12257-12261 (IDS filed 2/27/02). The rejection is maintained for the reasons of record, which are repeated for the convenience of the reader.

Hajduk et al., throughout the publication, and at the abstract, p. 12257, para 2-p. 12258, Table 1, Figures 2-4, teach identifying compounds that bind to macromolecules by one-dimensional NMR, which exploits changes in either the relaxation rates or diffusion rates of a small compound, that occurs upon binding to the biomolecules. Hajduk et al., teaches a mixture of 2-phenylimidazole, which binds to the FK506 binding protein (FKBP) and eight compounds that do not bind to the protein; Figures 2-4 depict NMR plots of ¹H NMR spectra for 2-phenylimidazole alone and binding to FKBP; and spectra for the ligand 5-cyano-4'-hydroxybiphenyl, which binds to the matrix metalloproteinase stromelysin, and of said 5-cyano-4'-hydroxybiphenyl binding to the catalytic domain of the proteolytic enzyme stromelysin. Hajduk et al. also teach 5-cyano-4'-hydroxybiphenyl in combination with eight other compounds that do not bind stromelysin.

Response to Arguments [Previous Office Action]

Applicant argues that the reference of Hajduk et al. does not disclose exposing substrate, ligand or product of a target molecule with chemical compounds and generating a spectrum of that mixture. Furthermore, Hajduk et al. do not disclose exposing this mixture with a target molecule for one or more incubation times and comparing spectra of the target/compound/ligand mixture over time. Finally, Hajduk et al. do not monitor a signal generated by a substrate, ligand or product over time. Instead, Hajduk et al. observe the signal of a chemical compound in a single mixture. Thus Hajduk et al. do not identically show each and every element of the independent claims of this invention.

Applicant's arguments filed 03/25/2005 have been fully considered but they are not persuasive. Hajduk et al., at p. 12258, para 3-p. 12259, para 1, teach generating a spectrum of a mixture of test compounds (1, 3-10, see Figure 2), in the absence of the target FK506 binding protein (FKBP). Hajduk at p. 12258, para 4, states: "The signals corresponding to all of the compounds in the mixture (1, 3-10)

Art Unit: 1639

appear in this spectrum." Next the spectrum of the test compounds in the presence of FKBP was obtained, and compared to the first spectra. "From this difference spectrum, the compound that binds to FKBP can be readily identified from an analysis of the chemical shifts which correspond to those of the free molecule". Thus Hajduk et al. anticipate the claimed invention.

Response to Arguments

Applicant has amended the claims to be drawn to "substrate or product" rather than "substrate, product or ligand". Applicant argues that Hajduk does not teach spectra of a substrate or product of a target molecule.

Applicant's arguments entered 1/23/2006, have been fully considered but they are not persuasive. Claims must be given their broadest reasonable interpretation consistent with the supporting description. In re Hyatt, 211 F.3d 1367, 1372, 54 USPQ2d 1664, 1667 (Fed. Cir. 2000). The specification as filed does not provide a limiting definition of the terms "substrate" or "product". Applicant does not indicate whether or how the terms "substrate" or "product" distinguish over the prior art.

14. Claims 1-4, 6, 7, 9-11, 17 and 19 are rejected under 35 U.S.C. 102(a) as being anticipated by Fesik et al., (WO 98/48264). The rejection is maintained for the reasons of record, which are repeated for the convenience of the reader. It is noted that the claims were rejected over Fesik et al., (WO 98/48264) under 35 USC 102(b), which was an inadvertent mistake. As stated above, the claims are rejected under 35 USC 102 (a). The examiner regrets any inconvenience that this may have caused the applicant.

Fesik et al., (WO 98/48264), throughout the publication, and at p. 1, lines 2-4, p. 2, line 23-p. 3, line 12, p. 4, line 18-p.4, line 33, p. 7, line 32-p. 8, line 37, p. 10, lines 10-19, p. 10, line 35-p. 11, line 2,

Art Unit: 1639

teaches: a) generating a first T2- or diffusion-filtered proton spectrum of one or a mixture of chemical compounds; b) exposing one or a mixture of chemical compounds to the target molecule; c) generating a second T2- or diffusion filtered proton spectrum of one or a mixture of chemical compounds that has been exposed to the target molecule in step (b); and d) comparing said first and second T2- or diffusion-filtered proton spectra to determine differences between said first and said second spectra, the differences identifying the presence of one or more compounds that are ligands which have bound to the target molecule. Additional steps comprise the steps of e) generating a T2- or diffusion-filtered proton spectrum of each compound in the mixture f) exposing each compound in the mixture individually to the target molecule, g) generating a T2- or diffusion-filtered proton spectrum of each compound in the mixture after exposure to the target molecule h) comparing each spectrum generated in step g) to the first spectrum generated from the target molecule alone to determine differences in any of those compared spectra, the differences identifying the presence of a compound that is a ligand which has bound to the target molecule; wherein the target is a polypeptide, which is a biomolecule. Fesik et al. teaches use of a sample changer with a total of 60 samples that can be run unattended and computer programs to facilitate transfer and automatic processing of multiple one-dimensional NMR data.

Response to Arguments [Previous Office Action]

Applicant argues that the reference of Fesik (1998) does not disclose exposing substrate, ligand or product of a target molecule with chemical compounds and generating a spectrum of that mixture. Furthermore, Fesik et al. (1998), do not disclose exposing this mixture with a target molecule for one or more incubation times and comparing spectra of the target/compound/ligand mixture over time. Finally, Fesik et al. (1998), do not monitor a signal generated by a substrate, ligand or product over time. Instead, Fesik et al. examine only spectra of chemical compounds at a single time point, and not of substrate, ligand or product with chemical compound and target over time. Thus, Fesik et al. (1998), do not identically show each and every element of the independent claims of this invention.

Applicant's arguments filed 03/25/2005 have been fully considered but they are not persuasive. Fesik et al., (WO 98/48264), throughout the publication, and for example, at p. 1, lines 2-4, p. 2, line 23-p. 3, line 12, teach: a) generating a first T2- or diffusion-filtered proton spectrum of one or a mixture of chemical compounds; b) exposing one or a mixture of chemical compounds to the target molecule; c) generating a second T2- or diffusion filtered proton spectrum of one or a mixture of chemical compounds that has been exposed to the target molecule in step (b); and d) comparing said first and second T2- or diffusion-filtered proton spectra to determine differences between said first and said second spectra, the differences identifying the presence of one or more compounds that are ligands which have bound to the target molecule. Thus Fesik (1998), anticipates the claimed invention.

In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., that the reference of Fesik (1998), examines only spectra of chemical compounds at a single time point, and not of substrate, ligand or product with chemical compound and target over time) do not correspond to limitations recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

Response to Arguments

Applicant has amended the claims to be drawn to "substrate or product" rather than "substrate, product or ligand". Applicant argues that the prior art reference of Fesik I does not teach exposing substrate or product to a target molecule with chemical

compounds and generating a spectrum of the substrate or product. Applicant argues that Fesik I does not disclose obtaining at least one spectrum of the substrate or product to identify compounds that interact with the target molecule in a mixture comprising target molecule, chemical compound and substrate or product.

Applicant's arguments entered 1/23/2006, have been fully considered but they are not persuasive. Claims must be given their broadest reasonable interpretation consistent with the supporting description. In re Hyatt, 211 F.3d 1367, 1372, 54 USPQ2d 1664, 1667 (Fed. Cir. 2000). The specification as filed does not provide a limiting definition of the terms "substrate" or "product" or "chemical compound". Applicant does not indicate whether or how the terms "substrate" or "product" or "chemical compound" distinguish over the prior art.

As stated in the previous Office action, Fesik et al. I, (WO 98/48264), throughout the publication, and for example, at p. 1, lines 2-4, p. 2, line 23-p. 3, line 12, teach: a) generating a first T2- or diffusion-filtered proton spectrum of one or a mixture of chemical compounds

15. Claims 1-4, 6, 7, 9-11, 17 and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Fesik et al., (WO 97/18469). The rejection is maintained for the reasons of record, which are repeated for the convenience of the reader.

Fesik et al., (WO 97/18469), throughout the publication, and at p. 1, lines 2-4, p. 3, lines 7-28, p. 7, line 32-p. 8, line 2, p. 8, line 37-p. 9, line 28, p. 11, lines 32-36, p. 14, lines 10-17, p. 18, line 25-p. 31, line 9, teaches screening chemical compounds for binding to a given target biomolecule by a process

Art Unit: 1639

involving the steps of a) first generating a first two-dimensional $^{15}\text{N}/^1\text{H}$ NMR correlation spectrum of a ^{15}N -labeled target molecule; b) exposing the labeled target molecule to one or a mixture of chemical compounds; c) next, generating a second two-dimensional $^{15}\text{N}/^1\text{H}$ NMR correlation spectrum of the labeled target molecule that has been exposed to one or a mixture of compounds in step (b); and d) comparing said first and second two dimensional $^{15}\text{N}/^1\text{H}$ NMR correlation spectra to determine differences between said first and said second spectra, the differences identifying the presence of one or more compounds that are ligands which have bound to the target molecule. Fesik et al. teaches use of a sample changer with a total of 60 samples that can be run unattended and computer programs to facilitate transfer and automatic processing of multiple one-dimensional NMR data. Fesik et al. teach that individual compounds, which may be interpreted as targets, that can be selected *inter alia* on the basis of size (molecular weight = 100-300) and molecular diversity. Compounds in the collection can have different shapes (e.g., flat aromatic rings(s), puckered aliphatic rings(s), straight and branched chain aliphatics with single, double, or triple bonds) and diverse functional groups (e.g., carboxylic acids, esters, ethers, amines, aldehydes, ketones, and various heterocyclic rings) for maximizing the possibility of discovering compounds that interact with widely diverse binding sites.

Response to Arguments [Previous Office Action]

Applicant argues that the reference of Fesik (1997) does not disclose exposing substrate, ligand or product of a target molecule with chemical compounds and generating a spectrum of that mixture. Furthermore, Fesik et al. (1997), do not disclose exposing this mixture with a target molecule for one or more incubation times and comparing spectra of the target/compound/ligand mixture over time. Finally, Fesik et al. (1997), do not monitor a signal generated by a substrate, ligand or product over time. Instead, Fesik et al. (1997) examine only spectra of chemical compounds at a single time point, and not of substrate, ligand or product with chemical compound and target over time. Thus, Fesik et al. (1997), do not identically show each and every element of the independent claims of this invention.

Applicant's arguments filed 03/25/2005 have been fully considered but they are not persuasive. Fesik et al., (WO 97/18469), at p. 18, lines 24-37, teach mixing ^{15}N -labeled stromelysin (reading on a ligand), with chemical compounds that are acetohydroxamic acid, CaCl_2 , sodium azide and TRIS buffered solution and generating a first spectrum, followed by exposing the mixture (absent evidence to the contrary), to "test compounds", which read on targets. A second spectrum was generated, (see, also p. 7, line 32-p.8, line 9), to thereby identifying the stromelysin as binding to a test compound.

Response to Arguments

Applicant has amended the claims to be drawn to "substrate or product" rather than "substrate, product or ligand". Applicant argues that the prior art reference of Fesik II does not teach exposing substrate or product to a target molecule with chemical compounds and generating a spectrum of the substrate or product.

Applicant's arguments entered 1/23/2006, have been fully considered but they are not persuasive. Claims must be given their broadest reasonable interpretation

Art Unit: 1639

consistent with the supporting description. In re Hyatt, 211 F.3d 1367, 1372, 54 USPQ2d 1664, 1667 (Fed. Cir. 2000). The specification as filed does not provide a limiting definition of the terms "substrate" or "product". Applicant does not indicate whether or how the terms "substrate" or "product" distinguish over the prior art.

New Claim Rejections

16. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

17. Claims 1, 2, 4-10, 18, and 19 are rejected under 35 U.S.C. 102(a) as being anticipated by Bleicher et al., J. Org. Chem. 1998, 63, 8486-8490.

The claims are drawn to methods of identifying compounds that interact with a target molecule comprising the steps of: a) mixing a substrate or product of a target with at least one chemical compounds; b) generating a first spectrum that displays either a chemical shift in the first dimension or a chemical shifts in the other dimension of substrate, product or ligand in step a); c) exposing substrate or product and mixture of chemical compounds in step a) to a target molecule for one or more incubation times; d) generating a second spectrum that displays either a chemical shifts in the first dimension or a chemical shifts in the other dimension of substrate or product in step a) that has been exposed to the target molecule in step c) in the presence of one or

Art Unit: 1639

mixture of chemical compounds in step a); e) comparing said first spectrum and second spectrum after one or more said incubation times in step c) to determine at least one difference between said first spectrum and second spectrum, the differences observed along either or both chemical shift dimensions identifying the transformation of said substrate and classifying the presence of one or more chemical compounds that interact with said target molecule; and variations thereof.

Bleicher et al., J. Org. Chem. 1998, 63, 8486-8490, throughout the publication, and especially at p. 8488, para 2-5, methods of identifying compounds that interact with a target molecule comprising the steps of: mixing, for example, three peptides, reading on a substrate or product of a target with at least one chemical compound; generating a first spectrum that displays either a chemical shift in the first dimension or a chemical shifts in the other dimension of the three peptides in the absence of vancomycin; c) exposing the mixture of the three peptides to a target molecule that is vancomycin, for one or more incubation times; d) generating a second spectrum that displays either a chemical shifts in the first dimension or a chemical shifts in the other dimension of the peptide that has been exposed to the vancomycin target molecule in the presence of the two other peptides; e) comparing said first spectrum and second spectrum after one or more said incubation times in step c) to determine at least one difference between said first spectrum and second spectrum, the differences observed along either or both chemical shift dimensions identifying the binding, reading on transformation, of said substrate or product peptide and classifying the presence of one or more peptide chemical compounds that bind with the vancomycin target molecule. Bleicher teaches a

Art Unit: 1639

target biomolecule that is vancomycin; one and two dimensional first and second spectrum; shifting of ^1H ; a mixture between 2 and 100 chemical compounds; 256 scans, which read on incubation times greater than 50; NMR spectra; a determining step by visual inspection; and apparent quenching of the reaction at a selected time

Conclusion

18. Claims 1-11 and 17-19 are rejected. Claims 5, 8 and 19 are objected to.

19. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mark L. Shibuya whose telephone number is (571) 272-0806. The examiner can normally be reached on M-F, 8:30AM-5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras can be reached on (571) 272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1639

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Mark L. Shibuya
Examiner
Art Unit 1639